Success Metrics

Clinical Success Rate
81.3%

Based on 13 completed trials

Completion Rate
81%(13/16)
Active Trials
50(51%)
Results Posted
15%(2 trials)
Terminated
3(3%)

Phase Distribution

Ph phase_3
7
7%
Ph phase_1
9
9%
Ph not_applicable
8
8%
Ph phase_2
32
33%
Ph phase_4
1
1%

Phase Distribution

9

Early Stage

32

Mid Stage

8

Late Stage

Phase Distribution57 total trials
Phase 1Safety & dosage
9(15.8%)
Phase 2Efficacy & side effects
32(56.1%)
Phase 3Large-scale testing
7(12.3%)
Phase 4Post-market surveillance
1(1.8%)
N/ANon-phased studies
8(14.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

59.1%

13 of 22 finished

Non-Completion Rate

40.9%

9 ended early

Currently Active

50

trials recruiting

Total Trials

98

all time

Status Distribution
Active(62)
Completed(13)
Terminated(9)
Other(14)

Detailed Status

Recruiting39
Completed13
unknown13
Not yet recruiting12
Active, not recruiting11
Withdrawn6

Development Timeline

Analytics

Development Status

Total Trials
98
Active
50
Success Rate
81.3%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (15.8%)
Phase 232 (56.1%)
Phase 37 (12.3%)
Phase 41 (1.8%)
N/A8 (14.0%)

Trials by Status

active_not_recruiting1111%
not_yet_recruiting1212%
completed1313%
unknown1313%
suspended11%
withdrawn66%
terminated33%
recruiting3940%

Recent Activity

Clinical Trials (98)

Showing 20 of 98 trialsScroll for more
NCT07258147Phase 2

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Not Yet Recruiting
NCT03876288

Gastroparesis Outcome Longitudinal Database Enrolled Numerically

Recruiting
NCT06974110Phase 1

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Recruiting
NCT06960889

A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients

Active Not Recruiting
NCT06660407Phase 2

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

Recruiting
NCT07522411Phase 1

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Not Yet Recruiting
NCT05178472Not Applicable

Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)

Recruiting
NCT07062055Phase 2

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Recruiting
NCT06719700Phase 2

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Recruiting
NCT04594187Phase 2

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

Recruiting
NCT07407166Not Applicable

Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

Recruiting
NCT06943235Phase 2

Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
NCT05863052

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Active Not Recruiting
NCT05488626Not Applicable

Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer

Withdrawn
NCT06810609Phase 2

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

Recruiting
NCT05978193Phase 2

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Recruiting
NCT04821843Phase 3

Neoadjuvant Treatment Modalities in Esophageal Cancer

Recruiting
NCT04821778Phase 3

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Recruiting
NCT06163053

A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

Completed
NCT04151940Not Applicable

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
98